Gregory Riely

Pulmonary and Respiratory Medicine · 2005–2023

A researcher in the Science corpus: 37 papers; trusts 3 researchers and is trusted by 3 researchers here, as inferred from the citation graph.

Subfields

Whom Gregory Riely trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. William Pao
  2. Vincent A. Miller

Who trusts Gregory Riely overall

  1. William Pao
  2. Shang-Gin Wu
  3. Adi F. Gazdar

Papers from Gregory Riely's perspective

Ordered by how strongly the researchers Gregory Riely trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification (Science)
  2. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. (Cancer Research)
  3. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways (Science)
  4. Targeted cancer therapy (Nature)
  5. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (The Lancet)
  6. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. (New England Journal of Medicine)
  7. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. (Proceedings of the National Academy of Sciences of the United States of America)
  8. Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib (Clinical Cancer Research)
  9. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M (Nature)
  10. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor (Science)

Their papers